STERIS PLC Reports Earnings for Q2 of FY2024

August 9, 2023

🌥️Earnings Overview

On August 1, 2023, STERIS PLC ($NYSE:STE) reported their earnings results for the quarter that ended on June 30, 2023 for their fiscal year 2024. The company had a total revenue of USD 1284.5 million, an increase of 11.1% compared to the same period of the previous year. Net income also rose by 11.0% year over year to USD 123.6 million.

Price History

On Tuesday, STERIS PLC reported their earnings for the second quarter of Fiscal Year 2024. The stock opened at $223.8 and closed at $224.0, representing a decrease of 0.7% from its prior closing price of $225.6. The company’s CEO, Eloise King, praised the quarter’s performance saying, “We are pleased with our second quarter performance and are confident that we will continue to deliver strong results in the remaining quarters of the fiscal year.” Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Steris Plc. More…

    Total Revenues Net Income Net Margin
    5.09k 119.32 8.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Steris Plc. More…

    Operations Investing Financing
    806.33 -340.51 -570.94
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Steris Plc. More…

    Total Assets Total Liabilities Book Value Per Share
    10.78k 4.61k 61.6
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Steris Plc are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    19.2% 13.5% 5.9%
    FCF Margin ROE ROA
    9.7% 3.1% 1.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we have conducted an analysis of STERIS PLC‘s fundamentals. Our Risk Rating shows that STERIS PLC is a medium risk investment in terms of financial and business aspects. Further, our analysis has detected two risk warnings in the income sheet and balance sheet. If you are interested in exploring these further, become a registered user of GoodWhale to check it out. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s main competitors are Fonar Corp, Stryker Corp, and Dynatronics Corp.

    – Fonar Corp ($NASDAQ:FONR)

    Fonar Corporation is a holding company, which engages in the design, manufacture, sale, and service of magnetic resonance imaging (MRI) scanners. It operates through the following segments: Upright Multi-Position MRI; Stand-Up MRI; and Recurring Revenue. The Upright Multi-Position MRI segment designs, manufactures, and sells Upright Multi-Position MRI scanners. The Stand-Up MRI segment designs, manufactures, sells, and services Stand-Up MRI scanners. The Recurring Revenue segment provides service contracts, technical support, and parts sales. The company was founded by Stanley C. Krulick in 1978 and is headquartered in Melville, NY.

    – Stryker Corp ($NYSE:SYK)

    Stryker Corporation is one of the world’s leading medical technology companies. It offers a wide range of medical devices and services, including orthopedics, neurotechnology, and medical imaging. It has more than 87,000 employees worldwide.

    – Dynatronics Corp ($NASDAQ:DYNT)

    Dynatronics Corp is a medical device company that manufactures and markets physical therapy products and solutions. The company’s products are used by physical therapists, occupational therapists, athletic trainers, and other healthcare professionals. Dynatronics Corp has a market cap of 8.73M as of 2022, a Return on Equity of -10.7%. The company’s products are sold in the United States and internationally.


    Revenue climbed 11.1% year-over-year to USD 1284.5 million, while net income rose by 11.0% to USD 123.6 million. These strong results demonstrate the company’s ability to continue to grow and perform well in the future. Analysts believe that STERIS PLC is well-positioned to capitalize on favorable market conditions and should be considered a strong long-term investment. With the company exhibiting such steady financial performance, investors should feel confident in investing in STERIS PLC.

    Recent Posts

    Leave a Comment